Longevity Health signs merger with 20/20 Biolabs; combined co. valued ~$99M

Longevity Health Holdings, Inc.

All-stock merger: 20/20 stockholders to own ~50.1% of combined co. (pre-concurrent financing).
Combined co. FY2025 revenue forecast to double to ~$7-8M from ~$3-4M; ~$1M synergies expected.
Post-closing: Jonathan Cohen (20/20 CEO) becomes CEO; Rajiv Shukla remains Chairman.
Concurrent financing to raise min. $4M gross proceeds; also at-market offering for up to $2M common stock.
Closing expected Q3 2025; subject to stockholder approvals, Nasdaq listing, and other conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.